- Home
- INNV vs MNPR Comparison
INNV vs MNPR Comparison
Compare INNV & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INNV
- MNPR
- Stock Information
- Founded
- INNV 2007
- MNPR 2014
- Country
- INNV United States
- MNPR United States
- Employees
- INNV N/A
- MNPR N/A
- Industry
- INNV Medical/Nursing Services
- MNPR Biotechnology: Pharmaceutical Preparations
- Sector
- INNV Health Care
- MNPR Health Care
- Exchange
- INNV Nasdaq
- MNPR Nasdaq
- Market Cap
- INNV 485.4M
- MNPR 390.5M
- IPO Year
- INNV 2021
- MNPR 2019
- Fundamental
- Price
- INNV $5.34
- MNPR $80.13
- Analyst Decision
- INNV Sell
- MNPR Strong Buy
- Analyst Count
- INNV 2
- MNPR 12
- Target Price
- INNV $5.00
- MNPR $96.64
- AVG Volume (30 Days)
- INNV 57.0K
- MNPR 81.8K
- Earning Date
- INNV 11-04-2025
- MNPR 11-07-2025
- Dividend Yield
- INNV N/A
- MNPR N/A
- EPS Growth
- INNV N/A
- MNPR N/A
- EPS
- INNV N/A
- MNPR N/A
- Revenue
- INNV $853,699,000.00
- MNPR N/A
- Revenue This Year
- INNV $10.61
- MNPR N/A
- Revenue Next Year
- INNV $10.14
- MNPR N/A
- P/E Ratio
- INNV N/A
- MNPR N/A
- Revenue Growth
- INNV 11.76
- MNPR N/A
- 52 Week Low
- INNV $2.60
- MNPR $4.50
- 52 Week High
- INNV $6.69
- MNPR $105.00
- Technical
- Relative Strength Index (RSI)
- INNV 53.78
- MNPR 50.93
- Support Level
- INNV $5.32
- MNPR $86.26
- Resistance Level
- INNV $6.16
- MNPR $104.00
- Average True Range (ATR)
- INNV 0.44
- MNPR 9.24
- MACD
- INNV -0.03
- MNPR -2.89
- Stochastic Oscillator
- INNV 41.12
- MNPR 23.44
About INNV InnovAge Holding Corp.
InnovAge Holding Corp is a healthcare delivery platform by several participants focused on providing all-inclusive, capitated care to high-cost, dual-eligible seniors. Its patient-centered care delivery approach improves the quality of care while keeping them in their homes and reducing over-utilization of high-cost care settings such as hospitals and nursing homes. The company's segment includes PACE and others. It generates maximum revenue from the PACE segment.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.